Ofatumumab – a new drug, new possibilities for treatment of relapsing forms of multiple sclerosis. Case reports Case report
Article Sidebar
Main Article Content
Abstract
Ofatumumab, a fully human anti-CD20 monoclonal antibody, has recently become a valuable therapeutic option for the treatment of patients with relapsed multiple sclerosis. As the only available anti-CD20 therapy administered by subcutaneous injection every 4 weeks. Ease of application and no need for hospitalization are also the advantages of the drug. Phase III clinical trials of ASCLEPIOS I/II demonstrated the efficacy of ofatumumab in reducing annual relapse rates and progression of clinical disability, as well as in inhibiting MRI lesions in patients with relapsed multiple sclerosis. We have an increasing amount of data, obtained both from the observational study (ALITHIOS) and from everyday clinical practice, on the high efficacy and safety profile of the drug. From November 2022 ofatumumab is also available in Poland as part of the B.29 drug program as a as a first-line therapy. This article presents cases of patients treated with ofatumumab.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. NFZ. NFZ o zdrowiu. Stwardnienie rozsiane Online.
3. Trojano M, Lucchese G, Graziano G et al. Geographical variations in sex ratio trends over time in multiple sclerosis PLoS One. 2012; 7(10): e48078.
4. Saidha S, Bell J, Harold S et al. Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis. Neurol Sci. 2023; 44(5): 1515-32.
5. de Sèze J, Maillart E, Gueguen A et al. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. Front Immunol. 2023; 14: 1004795.
6. Ministerstwo Zdrowia. Program lekowy; Leczenie Stwardnienia Rozsianego (ICD-10 G35).
7. Charakterystyka produktu leczniczego KESIMPTA (ofatumumab) (access: 22.03.2023).
8. Kappos L, Hauser SL. Therapy Session 3. Meet the Expert 2: Choosing therapy – similar compounds, same effect? ECTRIMS 2022.
9. von Essen R, Holm Hansen R, Højgaard C et al. Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022; 9: e200004.
10. Wiendl H, Fox E, Goodyear A et al. Effect of subcutaneous ofatumumab on lymphocyte subsets in patients with RMS: Analysis from the APLIOS study. Eur J Neurol. 2020; 27: 1301.
11. Hauser SL, Bar-Or A, Cohen JA et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis N Engl J Med. 2020; 383(6): 546-57.
12. Gärtner J, Hauser SL, Bar-Or A et al. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. Mult Scler. 2022; 28(10): 1562-75.
13. Cohen JA, Hauser SL, Cross AH et al. Five-Year Safety of Ofatumumab in People Living With Relapsing Multiple Sclerosis. Poster presentation at the American Academy of Neurology (AAN) 2023; April 22-27. Boston, MA, USA.
14. Cohen JA, Hauser SL, Zielman R et al. Effect of Longer-term Ofatumumab Treatment on Disability Worsening and Brain Volume Change. Oral presentation at the American Academy of Neurology (AAN) 2023; April 22-27, 2023; Boston, MA, USA.
15. Cutter G, Kappos L, Coyle et al. Improvement in Cognitive Processing Speed With Ofatumumab in Patients With Relapsing Multiple Sclerosis. Presented at the American Academy of Neurology 2023 Annual Meeting; April 22-27, 2023; Boston, MA, USA.